More than a weight-loss or diabetes drug
Most conversations about GLP-1 medications focus on weight loss or blood sugar control, but a growing body of large-scale clinical trial evidence shows several of these drugs directly reduce cardiovascular events — heart attacks, strokes, and cardiovascular death — independent of, and in addition to, their effects on weight. This is a meaningfully different, higher bar of evidence than "helps you lose weight, which is generally good for your heart" — these are dedicated cardiovascular outcomes trials designed specifically to test that question directly.
The landmark trials
LEADER (liraglutide). According to PubMed, this trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide or placebo. Liraglutide significantly reduced the primary composite outcome of cardiovascular death, non-fatal heart attack, or non-fatal stroke (13.0% vs. 14.9% with placebo), reduced cardiovascular death specifically (4.7% vs. 6.0%), and reduced death from any cause (8.2% vs. 9.6%) over a median follow-up of 3.8 years (Marso et al., New England Journal of Medicine, 2016, DOI (external link)). This was one of the first trials to establish that a GLP-1 medication could directly reduce cardiovascular events, not just improve risk factors like blood sugar.
SELECT (semaglutide). This trial extended the question to a different population: people with overweight or obesity and established cardiovascular disease, but without diabetes — testing whether the cardiovascular benefit held even outside a diabetes population. According to a related substudy publication, the main SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide compared to placebo in this population (Colhoun et al., Nature Medicine, 2024, DOI (external link)). The same substudy found semaglutide also improved kidney outcomes — a lower rate of significant kidney function decline and kidney disease progression — suggesting the cardiovascular benefit is part of a broader cardio-metabolic-kidney effect, not an isolated finding.
STEP-HFpEF (semaglutide, heart failure). Beyond heart attacks and strokes, semaglutide has also shown direct benefit for a specific type of heart failure (heart failure with preserved ejection fraction, or HFpEF) in patients with obesity — improving heart failure symptoms, physical function, and exercise capacity, alongside weight loss (see our related research summary in the suppression, satiation, and satiety guide for related trial context).
Class-wide evidence. According to PubMed, a large 2025 meta-analysis pooling 21 randomized controlled trials and 99,599 patients across eight different GLP-1 medications found conclusive, high-certainty evidence that GLP-1 receptor agonists as a class reduced all-cause death (12% reduction), cardiovascular death (13% reduction), and major adverse cardiovascular events (13% reduction) compared with placebo or controls, alongside reductions in heart attacks (15% reduction) and heart failure (15% reduction) (Galli et al., Journal of the American College of Cardiology, 2025, DOI (external link)). This is strong evidence that cardiovascular benefit is a class effect across multiple GLP-1 drugs, not limited to one specific medication.
Why these medications appear to help the heart
The exact mechanisms are still an active area of research, but several plausible, non-mutually-exclusive contributors are generally discussed:
- Weight loss itself reduces cardiovascular strain and improves several risk factors (blood pressure, cholesterol, blood sugar) that independently drive cardiovascular disease.
- Direct effects on blood vessels and inflammation. GLP-1 receptors are present in cardiovascular tissue, and there's evidence these medications may have direct anti-inflammatory and vascular effects separate from weight loss.
- Improved blood pressure and lipid profiles, which are well-documented secondary effects of GLP-1 treatment beyond the headline weight and blood sugar numbers.
- Reduced strain on the kidneys and heart together, given the interconnected nature of cardiovascular and kidney disease — consistent with the kidney benefit observed in the SELECT trial.
Important context and caveats
- The strongest evidence is in people who already have cardiovascular disease or significant risk factors — LEADER and SELECT both enrolled populations with diabetes or established cardiovascular disease. This doesn't mean there's no benefit for lower-risk individuals, but the strongest direct trial evidence is specifically in higher-risk populations.
- This is not the same across every GLP-1 medication or dose — the cardiovascular outcomes trials were conducted with specific drugs, doses, and populations, and results shouldn't be assumed to automatically generalize identically to every GLP-1 medication on the market, including newer ones without dedicated cardiovascular outcomes trials yet completed.
- Real-world results can differ from trial results. A 2025 review found real-world weight loss and adherence with GLP-1 medications tends to be lower than in controlled trials, with high discontinuation rates in the first year — a reminder that trial-level cardiovascular benefits are most likely to be realized with consistent, sustained use (Thomsen et al., Diabetes, Obesity & Metabolism, 2025, DOI (external link)).
- This doesn't replace other cardiovascular risk management — blood pressure medication, statins, and other established cardiovascular treatments remain important alongside, not instead of, GLP-1 therapy where appropriate.
The bottom line
Several GLP-1 medications have demonstrated genuine, trial-confirmed reductions in heart attacks, strokes, cardiovascular death, and heart failure — not just improved risk factors — in large randomized controlled trials, with a 2025 meta-analysis suggesting this is a broader class effect across multiple drugs. This evidence is strongest in people with existing cardiovascular disease or significant risk factors, and depends on consistent, sustained treatment to be realized in practice.